Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for Reversal in CABG Surgery
NCT03939923Phase 4Completed
- Sponsor
- West Virginia University
- Start
- May 2019
- Primary completion
- Jul 2021
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by West Virginia University. Primary endpoint: Time to Extubation at 3 days. Started May 2019; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03939923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939923.